Completed PHASE2 INTERVENTIONAL NCT00210288

Healthy Adult Volunteer Study for Two Doses of a Shigella Vaccine

A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of Two Doses 10^5 and 10^7 CFU of SC599 Oral Vaccine, a Live Attenuated Shigella Dysenteriae 1 Vaccine Strain in Healthy Human Adult Volunteers

Sponsor: Institut Pasteur

Conditions Shigella Infection

Interventions SC599

Updated 6 times since 2017 Last updated: Aug 7, 2018 Started: May 31, 2005 Primary completion: Sep 30, 2006 Completion: Apr 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Shigella Infection and is currently completed. Institut Pasteur leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Sep 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut Pasteur

Data source: Institut Pasteur

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom
• Paris, France